Open Market Through Stock Exchange | ₹25.00 Crores | Listing at BSE, NSE | Mon, Nov 21, 2022 - Wed, May 3, 2023
Windlas Biotech Ltd. Buyback is a tender offer for the repurchase of up to equity shares at a buyback price of ₹325 per share with a face value of ₹5 per share, aggregating to ₹25.00 crores.
The buyback opens on Nov 21, 2022 and closes on May 3, 2023.
Corporate Professionals Capital Pvt.Ltd. is the Manager to the Buyback and MUFG Intime India Pvt.Ltd. is the Registrar and SMC Global Securities Limited is the Registered Broker to the Buyback.
Investors are advised to refer to the Windlas Biotech Ltd. Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Mon, Nov 21, 2022
Offer Closing Date
Wed, May 3, 2023
Buyback Price
₹325 per share
Record Date
[.]
| Period Ended | Total Revenue | Profit After Tax | Net Worth |
|---|---|---|---|
| 31-Mar-20 | 331.34 | 23.68 | 209.66 |
| 31-Mar-21 | 430.7 | 15.74 | 199.12 |
| 31-Mar-22 | 472.64 | 38.09 | 394.78 |
| Amount in ₹ Crore | |||
Incorporated in 1991, Windlas Biotech Limited is in the business of providing pharmaceutical services. The company manufactures solid and liquid pharmaceutical dosage forms and provides a comprehensive range of services and specialized capabilities that include product discovery, product development, licensing, and commercial manufacturing of generic products.
Windlas Biotech markets their own manufactured authentic nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities at affordable prices. The company is associated with more than 100 leading Domestic Pharmaceuticals/MNCs.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jan-2022 | 244.70 | 212.15 | 232.89 |
| Jan-2022 | 261.20 | 219.00 | 241.72 |
| Jan-2022 | 232.90 | 203.55 | 217.81 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jan-2022 | 244.80 | 212.00 | 227.41 |
| Jan-2022 | 261.90 | 216.30 | 241.83 |
| Jan-2022 | 233.95 | 209.70 | 218.71 |
The buyback is being undertaken for the following reason:
1.To return surplus funds to the equity shareholders of the Company.
2. To improve return on equity, by reducing in equity base, thereby leading to a long-term increase in the value of shareholders.
Windlas Biotech Ltd.
705-706, Vatika Professional Point,
Sector-66
Golf Course Extension Road, Gurgaon,122001
Gurugram, Haryana, 122001
Lead Manager(s)
Registered Broker
The Windlas Biotech Buyback 2022 opens on November 21, 2022, and closes on May 3, 2023.
The Windlas Biotech Buyback 2022 is a Open Market Through Stock Exchange.
Windlas Biotech Buyback 2022 Schedule
| Buyback Opening Date | November 21, 2022 |
| Buyback Closing Date | May 3, 2023 |
| Last date for acceptance of shares | Upon relevant pay-out by the Stock exchange |
The Windlas Biotech Buyback 2022 is being offered at Rs ₹325 per share.
There is no ratio applicable in case of open market offer through stock exchange mechanism.
The Windlas Biotech Buyback 2022 has announced a buyback for an aggregate amount of not more than Rs. ₹25.00 Crores with pricing of Rs. ₹325 per share.
The buyback is being undertaken for the following reason:
1.To return surplus funds to the equity shareholders of the Company.
2. To improve return on equity, by reducing in equity base, thereby leading to a long-term increase in the value of shareholders.
Any equity shareholder holding the shares in Demat form can participate in the buyback offer through their stockbroker. The physical shareholder can participate only once the shares get converted into a Dematerialized form.
The shareholder needs to inform their broker on the details of the Equity shares they wish to sell. The broker will place a sell order whenever the company places a buy order for the buyback. The trade would get executed at the offer price or lesser only when the price offered by the shareholder matches with the buy order placed by the company.
The Windlas Biotech Buyback 2022 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
